Léčivé látky ve výzkumu
Naši pracovníci ve výzkumu a vývoji se soustřeďují na mechanismy vzniku a rozvoje onemocnění mozku. Směřujeme společně k cíli přinést nové přístupy k léčbě, které stanoví novou definici standardní péče o pacienty a prozkoumávat oblasti, kde je největší nenaplněná potřeba léčby.
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | Filing | ||||
---|---|---|---|---|---|---|---|---|---|
Brexpiprazole⁵ | PTSD⁶ | Filing | |||||||
Mechanizmus účinku Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 | |||||||
Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||||
Mechanizmus účinku Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
MAGLi program⁸ | Neurology | 1 |
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | |||||
---|---|---|---|---|---|---|---|---|---|
Amlenetug (anti α-synuclein mAb) | Multiple System Atrophy | 3 | |||||||
Mechanizmus účinku Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. |
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | |||
---|---|---|---|---|---|---|---|
Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
Project | Biology | Area | Phase 1 |
Phase 2 |
Phase 3 |
Filing/ Launch |
Mode of action |
---|---|---|---|---|---|---|---|
Eptinezumab (anti-CGRP mAb)¹ |
Hormonal / neuropeptide signaling | Migraine prevention² | ✔ | Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||
Lu AG09222 (anti-PACAP mAb)³ |
Hormonal / neuropeptide signaling | Migraine prevention | ✔ | Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |
|||
Lu AG13909 (anti-ACTH mAb)⁴ |
Hormonal / neuropeptide signaling | Neurohormonal dysfunctions | ✔ |
|
|||
Brexpiprazole5 | Circuitry / neuronal biology | PTSD6 | ✔ | Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. |
|||
Bexicaserin (5HT2C agonist) | Circuitry / neuronal biology | Developmental and Epileptic Encephalopathies | ✔ |
|
|||
Lu AF28996 (D1-D2 agonist)7 | Circuitry / neuronal biology | Parkinson’s disease | ✔ | Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||
MAGLi program8 | Circuitry / neuronal biology | Neurology | ✔ |
|
|||
Amlenetug (anti α-synuclein mAb) | Protein aggregation, folding and clearance | Multiple System Atrophy | ✔ |
|
|||
Lu AG22515 (CD40L blocker)9 | Neuroinflammation / neuroimmunology |
Neurology | ✔ |
|
Project | Biology | Area | Status | Mode of action | ||||
---|---|---|---|---|---|---|---|---|
Eptinezumab (anti-CGRP mAb)¹ |
Hormonal / neuropeptide signaling | Migraine prevention² | Launch / Filing | Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
||||
Lu AG09222 (anti-PACAP mAb)³ |
Hormonal / neuropeptide signaling | Migraine prevention | Phase 2 | Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |
||||
Lu AG13909 (anti-ACTH mAb)⁴ |
Hormonal / neuropeptide signaling | Neurohormonal dysfunctions | Phase 1 |
|
||||
Brexpiprazole5 | Circuitry / neuronal biology | PTSD6 | Launch / Filing | Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. |
||||
Bexicaserin (5HT2C agonist) |
Circuitry / neuronal biology | Developmental and Epileptic Encephalopathies | Phase 1 | Bexicaserin (LP352) is an oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with DEEs such as Dravet syndrome, Lennox-Gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other epileptic disorders. Bexicaserin is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. It was designed to be more specific and selective for the 5-HT2C receptor subtype, giving it the potential to reduce seizures in patients with DEEs while overcoming the known or perceived safety limitations of available drugs in the 5-HT2 class. Bexicaserin has no detected activity at the 5-HT2B and 5-HT2A receptor subtypes. Longboard plans to advance bexicaserin (LP352) into a global Phase 3 program. Longboard reported topline data from a Phase 1b/2a clinical trial for bexicaserin, the PACIFIC Study, evaluating participants ages 12 to 65 years old with a broad range of DEEs. |
||||
Lu AF28996 (D1-D2 agonist)7 |
Circuitry / neuronal biology | Parkinson’s disease | Phase 1 | Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
||||
MAGLi program8 | Circuitry / neuronal biology | Neurology | Phase 3 |
|
||||
Amlenetug (anti α-synuclein mAb) |
Protein aggregation, folding and clearance | Multiple System Atrophy | Phase 3 |
|
||||
Lu AG22515 (CD40L blocker)9 |
Neuroinflammation / neuroimmunology |
Neurology | Phase 1 |
|
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | Filing | ||||
---|---|---|---|---|---|---|---|---|---|
Brexpiprazole⁵ | PTSD⁶ | Filing | |||||||
Mechanizmus účinku Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 | |||||||
Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||||
Mechanizmus účinku Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
MAGLi program⁸ | Neurology | 1 |
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | |||||
---|---|---|---|---|---|---|---|---|---|
Amlenetug (anti α-synuclein mAb) | Multiple System Atrophy | 3 | |||||||
Mechanizmus účinku Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. |
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | |||
---|---|---|---|---|---|---|---|
Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
Projekt | Oblast | Fáze 1 | Fáze 2 | Fáze 3 | |||
---|---|---|---|---|---|---|---|
Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
More from Lundbeck
Více z Lundbecku
Výzkum a vývoj
Výzkum a
vývoj nových a vylepšených léčiv je podstatou toho co děláme.
Toto je Lundbeck
Specializovaná
farmaceutická společnost zaměřená výhradně na mozková onemocnění.
Porozumění mozkovým onemocněním
Cesta ke zdraví mozku začíná pochopením chorob v mozku.